Autres langues Rigel Pharmaceuticals, Inc.

Actions

RIGL

US7665596034

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
1,1 ^USD	0,00 %		+1,85 %	-24,14 %

12/03	Rigel Pharmaceuticals annonce la nomination de Lisa Rojkjaer au poste de médecin-chef	CI
07/03	RIGEL PHARMACEUTICALS, INC. : Citigroup réitère son opinion positive sur le titre	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Rigel Pharmaceuticals : March 2024	16/04
Rigel Pharmaceuticals, Inc. Enters into Amendment No. 4 to that Certain Credit and Security Agreement	12/04
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	10/04
Rigel Announces Publication of Data on REZLIDHIA in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia and Lymphoma	05/04
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer	12/03
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer	12/03
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, vs. Street Est of $33.4M	05/03
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05/03
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS	28/02
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update	27/02
Rigel Pharmaceuticals Seeks Acquisitions	11/01
Rigel Pharmaceuticals Provides Business Update	09/01
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	05/01
Rigel Pharmaceuticals Enters Collaboration to Study Possible Treatment for Brain Tumors; Shares Rise	04/01
Rigel Pharmaceuticals, Inc. Announces Collaboration with Connect to Conduct a Phase 2 Trial of Olutasidenib in Glioma	04/01
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma	04/01
Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA in AML and Other Cancers	11/12
Rigel Pharmaceuticals, MD Anderson Partner for Research on New Rezlidhia Indications	08/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Rigel Pharmaceuticals, Inc.

Actions

RIGL

US7665596034

Autres langues

Filtres